ArticleBioconjugate chemistry2014
Molecular probes for imaging of hypoxia in the retina.
Article in Bioconjugate chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 49 citations in OpenAlex.
- Imaging of the retinal hypoxia: A journey from oxygen microelectrode to the first hypoxia imaging in the living retina.Progress in retinal and eye research · 2025Review
- Imaging Hypoxia to Predict Primary Neuronal Cell Damage in Branch Retinal Artery Occlusion.Microcirculation (New York, N.Y. : 1994) · 2024Article
- Peritoneal Infusion of Oxygen Microbubbles Alters the Metabolomic Profile of the Lung and Spleen in Acute Hypoxic Exposure.Bioengineering (Basel, Switzerland) · 2024Article
- Pimonidazole-alkyne conjugate for sensitive detection of hypoxia by Cu-catalyzed click reaction.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024Article
- Mural Serum Response Factor (SRF) Deficiency Provides Insights into Retinal Vascular Functionality and Development.International journal of molecular sciences · 2023Article
- Ocular Nanomedicine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- A Novel NIR Fluorescent Probe for Highly Selective Detection of Nitroreductase and Hypoxic-Tumor-Cell Imaging.Molecules (Basel, Switzerland) · 2021Article
- A novel method for visualizing and tracking endogenous mRNA in a specific cell population in pathological neovascularization.Scientific reports · 2021Article
- Targeted Imaging of VCAM-1 mRNA in a Mouse Model of Laser-Induced Choroidal Neovascularization Using Antisense Hairpin-DNA-Functionalized Gold-Nanoparticles.Molecular pharmaceutics · 2018Article
- A Probe for the Detection of Hypoxic Cancer Cells.ACS sensors · 2017Article
- ROCK-1 mediates diabetes-induced retinal pigment epithelial and endothelial cell blebbing: Contribution to diabetic retinopathy.Scientific reports · 2017Article
- In Vivo Imaging of Retinal Hypoxia Using HYPOX-4-Dependent Fluorescence in a Mouse Model of Laser-Induced Retinal Vein Occlusion (RVO).Investigative ophthalmology & visual science · 2017Article
- Hypoxia Induces Internalization of κ-Opioid Receptor.Anesthesiology · 2017Article
- Luminescent Probe Based Techniques for Hypoxia Imaging.Journal of nanomedicine research · 2017Article
- Diabetic Retinopathy: Battling the Global Epidemic.Investigative ophthalmology & visual science · 2016Article
- In Vivo Imaging of Retinal Hypoxia in a Model of Oxygen-Induced Retinopathy.Scientific reports · 2016Article
- In Vivo Chemiluminescent Imaging Agents for Nitroreductase and Tissue Oxygenation.Analytical chemistry · 2016Article
- Nanoengineering of therapeutics for retinal vascular disease.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2015Review
- Applications of azo-based probes for imaging retinal hypoxia.ACS medicinal chemistry letters · 2015Article
- Anti-angiogenic Therapy for Retinal Disease.Handbook of experimental pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Hypoxia has been associated with retinal diseases which lead the causes of irreversible vision loss, including diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration. Therefore, technologies for imaging hypoxia in the retina are needed for early disease detection, monitoring of disease progression, and assessment of therapeutic responses in the patient. Toward this goal, we developed two hypoxia-sensitive imaging agents based on nitroimidazoles which are capable of accumulating in hypoxic cells in vivo. 2-nitroimidazole or Pimonidazole was conjugated to fluorescent dyes to yield the imaging agents HYPOX-1 and HYPOX-2. Imaging agents were characterized in cell culture and animal models of retinal vascular diseases which exhibit hypoxia. Both HYPOX-1 and -2 were capable of detecting hypoxia in cell culture models with >10:1 signal-to-noise ratios without acute toxicity. Furthermore, intraocular administration of contrast agents in mouse models of retinal hypoxia enabled ex vivo detection of hypoxic tissue. These imaging agents are a promising step toward translation of hypoxia-sensitive molecular imaging agents in preclinical animal models and patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.